GlassScriptPhysician profile
Ghulam Shaikh
NPI 1073571733
$9,570.27
in general payments reported to CMS, 2019-2025
48 companies · $791 in 2025
The $791 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,105 · 2020: $992 · 2021: $1,727 · 2022: $1,627 · 2023: $1,739 · 2024: $1,589 · 2025: $791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,119.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,385.10 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Amgen INC. | $1,091.69 | 2019-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $1,037.24 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $771.38 | 2019-2025 | |
| Lilly USA, LLC | $669.64 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $651.07 | 2020-2025 | Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $594.07 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $351.49 | 2019-2023 | Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.31 | 2019-2025 | Jardiance, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $241.62 | 2019-2023 | Spravato |
| Sunovion Pharmaceuticals INC. | $230.64 | 2019-2022 | |
| Esperion Therapeutics, INC. | $217.67 | 2020-2024 | Nexletol |
| Pfizer INC. | $214.05 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $184.80 | 2019-2024 | Rexulti, Nuedexta |
| Bayer Healthcare Pharmaceuticals INC. | $160.14 | 2021-2024 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghulam Shaikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.